anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Ganirelix Acetate Injection is supplied in a carton containing one of the following:

Disposable, ready for use, single dose, sterile, prefilled 1 mL glass syringes containing 250 mcg/0.5 mL aqueous solution of Ganirelix Acetate closed with a rubber piston that does not contain latex. Each Ganirelix Acetate sterile, prefilled syringe is affixed with a 27 gauge × ½-inch needle closed by a needle shield of dry natural rubber/latex which comes into contact with this product. (See CONTRAINDICATIONS and PRECAUTIONS, General.), NDC No. 78206-138-01

Disposable, ready to use, single dose, sterile, prefilled 1 mL glass syringe containing 250 mcg/0.5 mL aqueous solution of Ganirelix Acetate closed with a plunger stopper. Each Ganirelix Acetate sterile, prefilled syringe is affixed with a 27 gauge x ½ inch staked needle closed by a rigid needle shield (RNS) not made with natural rubber latex, NDC No. 78206-138-02.
PURPOSE:To enable formation of stable liposome containing a substance unstable at a high temperature, at a temperature lower than a phase-transition temperature (Tc), by hydrating a liposome membrane component substance containing phospholipid and cholesterol at >=Tc. CONSTITUTION:Water is added to a liposome membrane component substance containing phospholipid (preferably hydrogenated natural lecithin or synthetic lecithin composed of saturated fatty acid composition) and cholesterol and preferably further a negatively charged substance (e.g. phosphatidic acid and dicetyl phosphate) as an anticoagulant, and the membrane is completely hydrated at >=Tc. The amounts of cholesterol and the negatively charged substance are 0.2-1.0pt.wt. and 0.1-0.3pt.wt. per 1pt.wt. of the phospholipid, respectively. The hydrated product is cooled to <=Tc, maintained at a temperature to keep a compounding drug component from deactivation, mixed with an aqueous solution of a drug and vigorously agitated to form liposome.
The present invention relates to a composition for preventing or treating diabetes, disbesity or diabetic complications, comprising an oxyntomodulin analog as an active ingredient. The invention also relates to a method for treating diabetes, diabesity or diabetic complications, comprising administering a pharmaceutically effective amount of an oxyntomodulin analog to a subject. The oxyntomodulin analog has a high ability to activate the GLP-1 receptor and the glucagon receptor, compared to native oxyntomodulin. The oxyntomodulin analog induces the expansion of beta-cells and increases insulin secretion, thereby reducing blood glucose levels that were increased due to a high-calorie and high-fat diet. The oxyntomodulin analog induces decreases in body weight and diet intake to improve insulin sensitivity and allow blood glucose levels, which are not controlled due to insulin resistance, to be maintained at normal levels. Thus, the oxyntomodulin analog can be effectively used to prevent or treat of diabetes and related diseases.
OBJECTIVE: SGLT-2i are increasingly recognized for their benefits in patients with cardiometabolic risk factors. Additionally, emerging evidence suggests potential applications in acute illnesses, including COVID-19. This systematic review aims to evaluate the effects of SGLT-2i in patients facing acute illness, particularly focusing on SARS-CoV-2 infection.
METHODS: Following PRISMA guidelines, a systematic search of PubMed, Scopus, medRxiv, Research Square, and Google Scholar identified 22 studies meeting inclusion criteria, including randomized controlled trials and observational studies. Data extraction and quality assessment were conducted independently.
RESULTS: Out of the 22 studies included in the review, six reported reduced mortality in DM-2 patients taking SGLT-2i, while two found a decreased risk of hospitalization. Moreover, one study demonstrated a lower in-hospital mortality rate in DM-2 patients under combined therapy of metformin plus SGLT-2i. However, three studies showed a neutral effect on the risk of hospitalization. No increased risk of developing COVID-19 was associated with SGLT-2i use in DM-2 patients. Prior use of SGLT-2i was not associated with ICU admission and need for MV. The risk of acute kidney injury showed variability, with inconsistent evidence regarding diabetic ketoacidosis.
CONCLUSION: Our systematic review reveals mixed findings on the efficacy of SGLT-2i use in COVID-19 patients with cardiometabolic risk factors. While some studies suggest potential benefits in reducing mortality and hospitalizations, others report inconclusive results. Further research is needed to clarify optimal usage and mitigate associated risks, emphasizing caution in clinical interpretation.
Moderate to severe premenstrual disturbances afflict up to 20 percent of women. Studies have shown the use of serotonin reuptake inhibitors (SRIs) during the luteal phase of the menstrual cycle to be effective in improving symptoms in women with premenstrual dysphoric disorder (PMDD). Unfortunately, SRI treatment has only been evaluated in controlled clinical trials, and evidence suggests that patients in these clinical trials are not representative of women commonly seen in clinical practice. Thus, the real-world feasibility of intermittent dosing is questionable.

Patients in this study receive sertraline (Zoloft) during the luteal phase of their menstrual cycle every month for 6 months. The dose may be modified based on structured interviews with the patients. Assessments include questionnaires and interviews which take place at study start, at midpoint, and at the end of the study.
CD38 is also expressed in a variety of hematological malignancies, including multiple myeloma. In the present invention, the inventors have obtained a novel antibody against CD38 that can be suitable for the production of bispecific antibodies as well as CAR-T cell populations. In particular, the inventors reported the development of Bi38-3, a novel bispecific T cell cement that targets CD38 on MM cells and constructs cytotoxic T cells via CD3 epsilon. Bi38-3 lacks the Fc region of the native mAb, which contributes to the resistance process, but triggers T cell proliferation, cytokine release and lysis of CD38 positive MM cells in vitro. Similarly, Bi38-3 induced autologous T cells to eliminate tumor plasma cells isolated from MM patients at diagnosis and at relapse. The cytotoxicity induced by Bi38-3 was limited to cells expressing high levels of CD38 and maintained the integrity of T, B and NK lymphocytes in vitro. Importantly, Bi38-3 rapidly reduced tumor cells in the mm1.s xenograft mouse model of human MM. In conclusion, the results show that the antibody of the invention is an effective reagent for specifically eliminating CD38 positive malignant cells, does not significantly affect CD38 low-expression cells, and is a novel immunotherapy tool hopefully treating malignant hematological diseases, particularly multiple myeloma.
Using a 2-day counterbalanced, within-subject repeated-measures design, 16 participants wore two mechanical compression devices, the commonly-used Kendall SCD Express 9525 (SCD) and the novel Recovery Force Movement and Compressions Device (RF-MAC) for 1 night each in their home while sleep was recorded with polysomnography. For each device, participants also completed questionnaires to assess usability, mobility, perceived noise disturbance, and perceived sleep disturbance.
INTRODUCTION: with imported malaria cases in a given population, the question arises as to what extent the local cases are a consequence of the imports or not. We perform a modeling analysis for a specific area, in a region aspiring for malaria-free status.
METHODS: data on malaria cases over ten years is subjected to a compartmental model which is assumed to be operating close to the equilibrium state. Two of the parameters of the model are fitted to the decadal data. The other parameters in the model are sourced from the literature. The model is utilized to simulate the malaria prevalence with or without imported cases.
RESULTS: in any given year the annual average of 460 imported cases, resulted in an end-of-year season malaria prevalence of 257 local active infectious cases, whereas without the imports the malaria prevalence at the end of the season would have been fewer than 10 active infectious cases. We calculate the numerical value of the basic reproduction number for the model, which reveals the extent to which the disease is being eliminated from the population or not.
CONCLUSION: without the imported cases, over the ten seasons of malaria, 2008-2018, the KwaZulu-Natal province would have been malaria-free over at least the last 7 years of the decade indicated. This simple methodology works well even in situations where data is limited.
PURPOSE:To obtain a liver disorder suppressant useful for preventing and treating liver disorder, comprising an oxazopyrroloquinoline as an active ingredient. CONSTITUTION:An oxazopyrroloquinoline shown by the formula (R is the same as R' of alpha-amino acid shown by the formula R'-CH(NH2)-COOH) and/or a salt thereof is contained as an active ingredient. The compound is properly blended with a surfactant, excipient, colorant, preservative, coating auxiliary, etc., and pharmaceutically manufactured to give the objective substance. The substance is pharmaceutically manufactured into oral administration state such as capsule, tablet, powder, etc., and a parenteral administration state such as injection or solution. Further a sustained release preparation is effective. The compound shown by the formula is obtained by reacting pyrroloquinolinequinone or a salt thereof with an alpha-amino acid, methylamine, etc., in the presence of oxygen. The compound shown by the formula extremely suppresses rise in glutamic acid-oxazoloacetate transaminase and glutamic acid-pyruvate transaminase and total bilirubin.
Participants will be administer the optimized caffeine recommendation (0-300mg/2 hr. up to 800mg/24 hr.) potentially using caffeinated and non-caffeinated gum, depending on optimized dosage, during both nights of Phase 2.
Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 1ml normal saline will be injected epidurally in Bupivacain- fentanyl (BF) Group, then a 16G Portex catheter was inserted for post- operative analgesia.
Nodular fasciitis (NF) is a benign and self-limiting fibroblastic proliferation that originates from the superficial fascia and extends into the subcutaneous tissue or muscle. It typically manifests in individuals aged 20 to 35 years, with rare occurrences observed in patients over the age of 60 years. We herein report a case involving a 75-year-old man with NF in the right vocal cord. The patient sought medical attention at the Department of Otolaryngology of our hospital because of a 1-month history of hoarseness and breathlessness. The diagnosis was unable to be confirmed through preoperative pathological examination. After admission to our hospital, various examinations were completed and surgical treatment was performed, and the postoperative histopathological findings revealed the presence of NF in the right vocal cord. NF of the vocal cord is a rare clinical entity. Given its rapid progression and propensity for marked infiltration, it often poses diagnostic challenges because it can mimic various malignant soft tissue tumors. Therefore, thorough exclusion of other neoplastic lesions is imperative prior to confirming the diagnosis of NF through pathological examination. Local surgical resection remains the primary treatment modality.
Store Levalbuterol Inhalation Solution, USP in the protective foil pouch at 20°- 25°C (68°- 77°F) [see USP Controlled Room Temperature]. Protect from light and excessive heat. Keep unopened vials in the foil pouch. Once the foil pouch is opened, the vials should be used within 2 weeks. Vials removed from the pouch, if not used immediately, should be protected from light and used within 1 week. Discard any vial if the solution is not colorless.

Rx only
The prevalence of Heart Failure depends on the definition applied, but is approximately 1-2% of the adult population in developed countries, rising to ≥10% among people \>70 years of age. Among people \>65 years of age presenting to primary care with breathlessness on exertion, one in six will have unrecognized HF. The lifetime risk of HF at age 55 years is 33% for men and 28% for women. The most recent European data (ESC-HF pilot study) demonstrate that 12-month all-cause mortality rates for hospitalized and stable/ambulatory HF patients were 17% and 7%, respectively, and the 12-month hospitalization rates were 44% and 32%, respectively. Modifying risk factors and dynamic change of the medical treatment may improve symptoms, quality of life and reduce hospitalization due to HF exacerbation. For this cause, the Heat Failure unit was established. The goal of the Heart Failure unit is to provide medical and nursing follow-up for severe HF patients with New York Heart Association Function III-IV in purpose to improve their quality of life and reduce hospitalizations. At each visit the patients will be evaluated by a nurse and a cardiologist, blood tests will be performed and IV treatment will be given as needed, including Furosemide, Iron, Dobutamine and Packed Cells.

The investigator is trying to improving our knowledge in the treatment of HF patients, for the purpose of improving their quality of life and reducing hospitalizations. For achieving this the investigator would like to build a registry which will include all the HF patients going an evaluation in the Heart Failure unit or clinic in our facility. Prospective registry which will include all the HF patients evaluated in the Heart Failure unit or clinic. The patients will sign an informed consent form. After filling the informed consent the patients will be evaluated for clinical history and physical examination by the nurse and a cardiologist. Then, the patients may perform the following test: ECG, Chest X-RAY, Blood test including: complete blood count, renal and liver function, electrolytes, thyroid function, cholesterol, glucose, Troponin and Brain Natriuretic Peptide. It is impotent to mentions that all of the test mentioned above are being performed as part as the Heart Failure unit treatment and none are being done for the purpose of the study. After completing the evaluation the patients will be treated as needed by IV medications such as Furosemide, Iron, Dobutamine and Packed Cells. The data collected will include demographic: gender, age, hospitalization, diagnosis, symptoms, clinical as well as laboratory, echocardiographic and echocardiogram findings.

Identified details will be separated in a way that will not enable to review them. All data handling and the separation of the identified data will be done by the Principal Investigator, or sub-investigator in this study, who is in charge of the hearing screening program in our institution.
Colchicine is a substrate of the efflux transporter P-glycoprotein (P-gp), and the CYP3A4 metabolizing enzyme. Fatal drug interactions have been reported when colchicine is administered with clarithromycin, a dual inhibitor of CYP3A4 and P-glycoprotein. Toxicities have also been reported when colchicine is administered with inhibitors of CYP3A4 that may not be potent inhibitors of P-gp (e.g., grapefruit juice, erythromycin, verapamil), or inhibitors of P-gp that may not be potent inhibitors of CYP3A4 (e.g., cyclosporine).

Patients with renal or hepatic impairment should not be given MITIGARE with drugs that inhibit both P-glycoprotein and CYP3A4 [see Contraindications(4)]. Combining these dual inhibitors with MITIGARE in patients with renal and hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. 

Physicians should ensure that patients are suitable candidates for treatment with MITIGARE and remain alert for signs and symptoms of toxic reactions associated with increased colchicine exposure due to drug interactions. Signs and symptoms of colchicine toxicity should be evaluated promptly and, if toxicity is suspected, MITIGARE should be discontinued immediately.
A computer site includes a data generating source. The source may include a device (e.g. a heart monitor) which may be manipulated by the patient to sense a biological function or condition such as a heart beat. The device outputs an audible signal in response to the monitored condition. A computer that can be operated by the patient or other initial user at the site runs a program that processes an electric signal generated in response to the audible signal as received through a microphone connected to the computer. The program is downloaded or otherwise accessed through a computer communications network (e.g. Internet). The computer sends resulting data signals over this network. Using a plurality of the foregoing components, any number of patients (or other users) that can access the computer communications network can provide real-time information about their personal medical condition (or other generated data) to their personal medical care providers (or other remote end users).
FIELD: medicine, oncology. SUBSTANCE: immunotherapeutic preparation is an antigenic or/and immunoregulating material obtained from Mycobacterium vaccae. Early this preparation has been used for immunotherapy of tuberculosis, leprosy and some autoimmune illnesses, for example, rheumatic arthritis. Invention ensures to enhance the effectiveness of immunotherapy of mesodermal, endodermal and ectodermal tumors including breast and bronchus tumors and can be used for retention or prevention of growth or proliferation of tumors. EFFECT: enhanced antitumor activity of an agent. 6 cl, 3 ex
Following the Stage 1 no treatment baseline assessment period, telapristone acetate (Proellex®) 6 mg capsules, orally once daily for 18 weeks in Stage 2. Eligible participants had the option to receive 2 additional 16-week cycles of active treatment at 6 mg/day separated by an ODI in Stage 3.
Participants will be treated with hyperbaric oxygen (HBO) therapy within three days of acute carbon monoxide poisoning. Treatment is a minimum of three inpatient sessions. Participants will also receive 10 mg dexamethasone per day while receiving HBO therapy (minimum of two doses, maximum of five doses if participants' stay is longer than three days). After three treatment sessions, participants will discharge home, barring no other medical complications requiring further hospitalization. In addition, continued HBO therapy plus steroids will be offered if participants are still dealing with CO poisoning sequelae as determined by study outcome measures.
INTRODUCTION: Procarbazine is an oral chemotherapeutic agent used in the treatment of brain malignancies and is associated with hypersensitivity reactions. In case of grade 4 reactions, rechallenge should be avoided, and the agent should be replaced, unless the treatment is curative, in which case the application of a desensitization protocol should be considered. We present a successful case of desensitization in procarbazine anaphylaxis.
CASE REPORT: A 53-year-old male patient was diagnosed with recurrent anaplastic oligodendroglioblastoma. The patient received three cycles of procarbazine, lomustine, and vincristine chemotherapy for malignancy recurrence. In the fourth cycle, on the 12th day of procarbazine treatment, the patient developed anaphylaxis. Procarbazine was given together with premedication as part of the 12-step desensitization process, and the fourth cycle was successfully completed.
MANAGEMENT AND OUTCOME: Procarbazine hypersensitivity reactions are observed less frequently than reactions to other chemotherapeutics. We presented a case of procarbazine-associated severe anaphylaxis that was able to continue procarbazine chemotherapy with successful desensitization. This case is important in terms of confirming the procarbazine desensitization protocol.
DISCUSSION: In literature there is only one protocol developed was successfully applied in one patient with procarbazine anaphylaxis. In the current case, we took this protocol into consideration in the management of our patient. Following the use of this protocol, the patient was able to continue procarbazine chemotherapy successfully. Procarbazine anaphylaxis is rare, and more cases are needed to be reported to confirm the desensitization protocol and when to continue procarbazine treatment.
OBJECTIVE: To estimate the association between disability and the demand for medical emergency care by citizens of Peru over the age of 18 years in 2019.
METHODS: Cross-sectional analysis of secondary data from the national survey of budgeted programs (ENAPRES, in its Peruvian abbreviation) of 2019. Disabilities were surveyed based on the criteria of the Washington Group on Disability Statistics. Medical emergencies were queried using 2 questions referring to life-threatening situations. Sociodemographic covariables and variables related to certain medical emergencies were also analyzed as possible confounders. Poisson regression analysis was carried out and crude and adjusted prevalence ratios calculated. Calculations were performed on a complex sample of data from the ENAPRES 2019 survey.
RESULTS: Data for 62 959 persons over the age of 18 years were included. Some type of disability was reported by 4.3% of the sample, and 8.7% reported a medical emergency during the past year. Persons with 3 or more disabilities were 2.97-fold more likely to have a medical emergency than persons without disabilities (prevalence ratio, 2.97 (95% CI, 2.28-3.87) after adjustment for multiple confounding variables.
CONCLUSIONS: Disabled persons were more likely to have medical emergencies than persons without disabilities in Peru in 2019. The likelihood of medical emergencies was slightly higher in those with 3 or more disabilities.
Subjects in Group B start with baseline conditions of pre-filter + HEPA + ESP in their offices and dorms. After a baseline biological measurement, they then receive a 5-week intervention in which the ESP is removed, leaving a pre-filter + HEPA combination. This intervention period includes a biological measurement 2 weeks into the intervention and other 4-5 weeks into the intervention. The baseline air purification conditions are then restored, and another biological measurement is taken 2 weeks after that.